Company Profile

Pieris Pharmaceuticals, Inc. is a, clinical-stage biotechnology company committing to providing novel solutions for oncology, respiratory disease and other therapeutic areas by applying its proprietary Anticalin® technology to create differentiated drugs.

In 2017, Pieris forged strategic alliances with Servier and AstraZeneca to accelerate its transformation into a fully-integrated, biologics R&D and commercial organization, focused on two immunology-related therapeutic areas: immuno-oncology and respiratory disease. The foundation of Pieris' partnerships and R&D efforts is a proprietary class of clinically-tested next generation therapeutics, Anticalin proteins.

Anticalin proteins are recombinantly engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. Our libraries of more than 100 billion different Anticalin proteins can virtually bind to any target of interest

Pieris Pharmaceuticals, Inc.

Investor Presentation

Pieris Pharmaceuticals, Inc.

2020 Annual Report

Pieris Pharmaceuticals, Inc.

Proxy Statement

Pieris Pharmaceuticals, Inc.

Fact Sheet


Stock Snapshot

PIRS Symbol
Nasdaq Market
Market Cap

Upcoming Events

2021 Annual Meeting of Stockholders

Virtual Meeting

Meeting Link:
View IR Calendar »